LENZ Therapeutics receives FDA approval for VIZZ (aceclidine) to treat presbyopia

LENZ Therapeutics, Inc.

• VIZZ (aceclidine ophthalmic solution) 1.44% approved by FDA for presbyopia, impacting ~128M US adults.
• First and only aceclidine-based eye drop; once-daily dosing with proven efficacy up to 10 hours.
• Samples and commercial availability expected as early as October 2025; sales activities to begin immediately.
• Approval based on three Phase 3 studies (CLARITY 1,2,3) showing rapid onset within 30 min and consistent near-vision improvement.
• Well-tolerated; most common adverse reactions were instillation site irritation, dim vision, headache, mostly mild and self-resolving.